5 December 2024: Study shows huge improvement in progression-free survival with adjuvant rituximab containing therapy. Newly published findings of extended follow-up from a TROG Cancer Research trial of radiotherapy plus chemo-immunotherapy in follicular lymphoma (TROG 99.03 – Follicular lymphoma) provide valuable evidence in support of changing the current standard
28 November 2024: In this Q&A, TROG President A/Prof Puma Sundaresan talks about her passion for patient-centred cancer care, her vision for TROG and future directions for radiation medicine research. Q: What attracted you to the field of radiation oncology, and drives your continued passion for this field? A:
November 2024: Congratulations to the Trek4TROG team for successfully completing our second annual fundraising hike in the Blue Mountains in October. The team of nine adventurous trekkers, including TROG staff and members, took on the challenge of a spectacular one-day hike through the Blue Mountains west of Sydney, to
24 October 2024: Newly published findings from the TROG 14.02 RAIDER trial offer promise for the use of complex adaptive radiotherapy as an alternative to radical surgery for bladder cancer. The RAIDER team published their significant phase II trial findings in the European Urology journal in October. The trial,
23 October 2024: TROG Cancer Research is thrilled to be among 14 clinical trial groups awarded new Cancer Australia funding with a combined total of almost $22.2 million to support vital work in improving cancer care and outcomes. Minister for Health and Aged Care, the Hon Mark Butler MP,
15 October 2024: TROG Cancer Research has made a commitment to embracing the principles of diversity, equity and inclusion (DEI) across all aspects of our work, with the launch of a new DEI policy. The Diversity, Equity and Inclusion (DEI) Policy provides guidelines to ensure DEI principles are embedded
12 September 2024: TROG Cancer Research has outlined how it plans to further the organisation’s vital work advancing and diversifying radiation medicine research over the next three years. The TROG Cancer Research Strategic Plan 2024-2026 outlines our strategic priorities, key initiatives that will be undertaken over the three-year-period, and
18 September 2024: We’re thrilled to announce the release of globally significant results from the AGITG TOPGEAR study on which TROG collaborated, providing practice-changing evidence about preoperative chemoradiotherapy for gastric cancer. The findings, announced simultaneously at the European Society for Medical Oncology Congress in Barcelona, Spain and published in
11 September 2024: Our 2024 Annual Scientific Meeting was a vital platform for advancing cutting-edge research in radiation therapy and enhancing collaboration among researchers from Australia, New Zealand and beyond. More than 250 delegates joined together for the TROG Cancer Research 36th ASM, held in our hometown of Newcastle,
The 2023 TROG Cancer Research Annual Report details achievements including strengthened collaborations and growth in membership.
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Latest News
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292
